Boxed Warning Removal on Menopause Hormone Products

The U.S. Food and Drug Administration changed what the boxed warning on menopausal hormone therapy says. The wording of that change, and of the 2003 labeling changes before it, is the subject of this page.
What the agency took out
The U.S. Food and Drug Administration wrote that risk statements related to cardiovascular disease, breast cancer and probable dementia were removed from the boxed warning, the agency's most prominent safety-related warning.
Three risk statements are named: cardiovascular disease, breast cancer and probable dementia. The agency also describes the boxed warning as its most prominent safety-related warning, so the removal is from the loudest place on the label. The sentence says the statements left the boxed warning. It does not say what the rest of the label contains. The agency's own reference, the FDA's menopause page, gives the wider context.
Where the labeling story starts
The U.S. Food and Drug Administration wrote that, based on the WHI findings, in 2003 it began approving class-wide labeling changes for estrogen plus progestogen and estrogen-alone products approved for several uses, including prevention of postmenopausal osteoporosis.
The sentence names its basis, the WHI findings, its year, 2003, and its scope, class-wide. "Class-wide" points to a group of products rather than a single brand.
Where common claims go past the text
A line such as "the warning is gone" goes further than the agency's sentence, which names three removed risk statements. A line calling hormone therapy risk-free is not in either passage. Both agency sentences describe labeling changes. Neither describes a change in what any individual patient faces.
What the wording leaves open
Neither passage says what a particular patient's risk looks like after the change. Readers in Berkeley Heights, New Jersey weighing a menopause hormone product can ask the prescriber to read the current label with them, since labels are the documents that get revised. The Endocrine Society keeps a general menopause reference for patients that sits alongside the agency pages.